Verastem, Inc. (VSTM)
VSTM Stock Price Chart
Explore Verastem, Inc. interactive price chart. Choose custom timeframes to analyze VSTM price movements and trends.
VSTM Company Profile
Discover essential business fundamentals and corporate details for Verastem, Inc. (VSTM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Jan 2012
Employees
78.00
Website
https://www.verastem.comCEO
Daniel W. Paterson
Description
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
VSTM Financial Timeline
Browse a chronological timeline of Verastem, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.46, while revenue estimate is $22.88m.
Earnings released on 7 May 2026
EPS came in at -$0.37 surpassing the estimated -$0.46 by +19.57%, while revenue for the quarter reached $18.67m , missing expectations by -12.87%.
Earnings released on 4 Mar 2026
EPS came in at -$0.39 surpassing the estimated -$0.49 by +20.41%, while revenue for the quarter reached $17.54m , beating expectations by +3.73%.
Earnings released on 4 Nov 2025
EPS came in at -$1.35 falling short of the estimated -$0.51 by -164.71%, while revenue for the quarter reached $11.24m , missing expectations by -31.99%.
Earnings released on 7 Aug 2025
EPS came in at -$0.39 surpassing the estimated -$0.85 by +54.12%, while revenue for the quarter reached $2.14m , missing expectations by -62.49%.
Earnings released on 13 May 2025
EPS came in at -$0.96 falling short of the estimated -$0.72 by -33.33%.
Earnings released on 20 Mar 2025
EPS came in at -$1.33 falling short of the estimated -$0.81 by -64.20%, while revenue for the quarter reached $9.98m , beating expectations by +6.55k%.
Earnings released on 6 Nov 2024
EPS came in at -$0.60 surpassing the estimated -$0.71 by +15.49%.
Earnings released on 8 Aug 2024
EPS came in at -$0.31 surpassing the estimated -$1.06 by +70.75%, while revenue for the quarter reached $10.00m , beating expectations by +19.90k%.
Earnings released on 9 May 2024
EPS came in at -$1.26 falling short of the estimated -$1.16 by -8.62%.
Earnings released on 14 Mar 2024
EPS came in at -$1.02 falling short of the estimated -$0.82 by -24.39%, while revenue for the quarter reached $114.00k , missing expectations by -97.76%.
Earnings released on 8 Nov 2023
EPS came in at -$0.75 surpassing the estimated -$0.92 by +18.48%.
Earnings released on 8 Aug 2023
EPS came in at -$1.37 falling short of the estimated -$1.13 by -21.24%.
Stock split effective on 1 Jun 2023
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 May 2023
EPS came in at -$0.96 surpassing the estimated -$1.08 by +11.11%.
Earnings released on 14 Mar 2023
EPS came in at -$0.96 falling short of the estimated $0.10 by -1.06k%, while revenue for the quarter reached $2.60m .
Earnings released on 3 Nov 2022
EPS came in at -$1.08 surpassing the estimated -$1.44 by +25.00%.
Earnings released on 8 Aug 2022
EPS came in at -$1.44 falling short of the estimated -$1.32 by -9.09%.
Earnings released on 9 May 2022
EPS came in at -$1.08 falling short of the estimated -$0.96 by -12.50%, while revenue for the quarter reached $2.60m , beating expectations by +73.07%.
Earnings released on 28 Mar 2022
EPS came in at -$1.08 falling short of the estimated -$0.96 by -12.50%, while revenue for the quarter reached $545.00k , beating expectations by +990.00%.
Earnings released on 4 Nov 2021
EPS came in at -$1.56 falling short of the estimated -$1.08 by -44.44%, while revenue for the quarter reached $2.00k , beating expectations by +9.11%.
Earnings released on 2 Aug 2021
EPS came in at -$1.20 falling short of the estimated -$1.08 by -11.11%, while revenue for the quarter reached $500.00k , beating expectations by +900.00%.
VSTM Stock Performance
Access detailed VSTM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
